Page 15 - டியூக் மருத்துவ ஆராய்ச்சி நிறுவனம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
CDC and NIH bring COVID-19 self-testing to residents in two locales
nih.gov - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nih.gov Daily Mail and Mail on Sunday newspapers.
CDC and NIH bring COVID-19 self-testing to residents in two locales
nih.gov - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nih.gov Daily Mail and Mail on Sunday newspapers.
Data-Driven: Research Collaborative Guides Reopening Decisions
thepilot.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thepilot.com Daily Mail and Mail on Sunday newspapers.
March 16, 2021
Patients with a history of cocaine use who present with non-ST-segment elevation myocardial infarction have a lower risk of future major adverse cardiovascular events if treated invasively rather than with a more-conservative approach, according to a new retrospective study.
Overall, invasive management, which included coronary angiography followed by PCI or CABG if needed, lowered the risk of MACE at 6 months by 28% compared with a noninvasive strategy.
The results, however, point to one of the major challenges in treating patients with cocaine-associated NSTEMI, namely their ability to adhere to posttreatment dual antiplatelet therapy (DAPT). While there was no greater risk of emergent revascularization in the overall cohort, that risk was significantly elevated among patients deemed nonadherent to medical therapy who’d been treated with a drug-eluting stent, report researchers.
(1)
Centessa Pharmaceuticals ( Centessa ), a pharmaceutical company consisting of 10 subsidiary companies advancing a portfolio of high conviction programs with strong biological validation, today announced key additions to its leadership team. Gregory Weinhoff, M.D., MBA, joined the team as chief financial officer, while Mary Lynne Hedley, Ph.D., Robert M. Califf, M.D., MACC, and Samarth Kulkarni, Ph.D., joined Centessa s board of directors effective February 23, 2021. Centessa launched last month with a goal of redefining pharmaceutical R&D productivity through an asset-centric model that we believe has the potential to support the advancement of novel programs by industry-leading experts in their respective fields, said Saurabh Saha, M.D., Ph.D., chief executive officer of Centessa. Each member of our team brings industry-leading qualifications and differentiated perspectives to help guide the expansion of our organization. We are thrilled to welcome Greg, Mary Lynne, Robert